NEUROCRINE BIOSCIENCES INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B |
| Cost of revenue | $52.1M | $34.0M | $39.7M | $23.2M | $14.3M |
| Selling, general & administrative | $1.2B | $1.0B | $887.6M | $752.7M | $583.3M |
| Research and development | $1.0B | $731.1M | $565.0M | $463.8M | $328.1M |
| Operating expenses | — | — | — | — | $1.0B |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M |
| Interest expense | — | — | $4.6M | $7.1M | $25.8M |
| Pretax income | $705.4M | $486.0M | $332.1M | $213.9M | $101.4M |
| Income tax expense | $226.8M | $144.7M | $82.4M | $59.4M | $11.8M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M |
| Balance Sheet | |||||
| Cash and equivalents | $713.0M | $233.0M | $251.1M | $262.9M | $340.8M |
| Current assets | $2.5B | $1.7B | $1.6B | $1.5B | $972.8M |
| Total assets | $4.6B | $3.7B | $3.3B | $2.4B | $2.1B |
| Current liabilities | $743.4M | $507.7M | $654.8M | $537.7M | $245.8M |
| Total liabilities | $1.4B | $1.1B | $1.0B | $660.9M | $698.5M |
| Stockholders' equity | $3.3B | $2.6B | $2.2B | $1.7B | $1.4B |
| Cash Flow Statement | |||||
| Cash from operations | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M |
| Depreciation and amortization | $26.0M | $23.5M | $17.8M | $15.1M | $10.9M |
| Stock-based compensation | $217.9M | $195.5M | $194.3M | $173.1M | $134.2M |
| Capital expenditure | $34.0M | $38.2M | $28.3M | $16.5M | $23.4M |
| Free cash flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M |
| Share repurchases | $167.7M | $300.0M | $0 | $0 | — |
Shares outstanding 100.5M · Free float 84.3%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.